The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The product basket increased to 1800 medicines and 285 Surgical Equipment
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Take proper precautions and seek timely treatment!
Marks the World Head & Neck Cancer Day at the OCTF Conference
CARA is a data and content management platform that helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Apollo Transplant program is the first program in India to cross the landmark of 18500 kidney transplants, 4300 liver transplants and 500 pediatric liver transplants
Subscribe To Our Newsletter & Stay Updated
